Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from an ongoing phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC).

Ipsen (Euronext: IPN; ADR: IPSEY) and Servier announced today initial safety and efficacy data from Part 1 of the Phase II/III RESILIENT study of investigational liposomal irinotecan (ONIVYDE®) in ...

The US Food and Drug Administration (FDA) has approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) in combination with oxaliplatin, fluorouracil, and leucovorin for the first-line ...

July 1 (Reuters) - IPSEN SA: * IPSEN PRESENTS PHASE I/II CLINICAL DATA EVALUATING LIPOSOMAL IRINOTECAN (ONIVYDE®) AS AN INVESTIGATIONAL FIRST-LINE COMBINATION TREATMENT FOR METASTATIC PANCREATIC ...

Ipsen has initiated the NAPOLI-3 Phase III clinical study (NCT04083235) comparing the safety and efficacy of liposomal irinotecan + 5-fluorouracil/leucovorin (5-FU/LV ...

Please provide your email address to receive an email when new articles are posted on . Irinotecan liposome injection combined with 5-FU/leucovorin and oxaliplatin prolonged OS compared with ...

– Treatment emergent adverse events Grade 3 or higher were reported by 20 of 32 patients from the 50/60[*] dose pooled patient analysis; no patient reported Grade 3 or higher fatigue or peripheral ...

The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). Patients with SCLC and progression on or after first-line ...

SAN FRANCISCO -- A four-drug chemotherapy combination coaxed a statistically significant 2-month improvement in overall survival (OS) in untreated metastatic pancreatic cancer versus a ...

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has completed its acquisition of global oncology assets from Merrimack Pharmaceuticals, in Cambridge, ...

– 44% of patients achieved a response and nearly half (48%) maintained disease control at week 12 (efficacy as secondary endpoint) – – Treatment emergent adverse events Grade 3 or higher were reported ...